1-(3-bromophenyl)-2-methylpropan-1-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-bromophenyl)-2-methylpropan-1-ol
• 化学式: C₁₀H₁₃BrO
• 分子量: 229.117
• InChiKey: MEWCGLMNRLEPCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(3-bromophenyl)-2-methylpropan-1-ol 在 aluminum oxide 、 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以2.1 g的产率得到1-(3-溴苯基)-2-甲基-1-丙酮
  参考文献：
  名称：

  Dual Role of Alkynyl Halides in One-Step Synthesis of Alkynyl Epoxides

  摘要：

  It was demonstrated that alkynyl halides could serve as a source of Br+ and acetylide ions in the same transformation. This allowed for the efficient one-step preparation of alkynyl epoxides, important organic building blocks, from readily available starting materials.

  DOI：

  10.1021/ja806178r
• 作为产物：
  描述：

  间溴苯甲醛 、 异丙基氯化镁 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 1-(3-bromophenyl)-2-methylpropan-1-ol
  参考文献：
  名称：

  Dihydropyrazolopyrimidinone derivatives

  摘要：

  该发明涉及一般式（I）的化合物，其中Ar1是可选择取代的芳基或杂环芳基；R1是可选择取代的较低烷基、较低烯烃基、较低炔烃基或环状较低烷基基团，或是具有取代基的芳基、芳基烷基或杂环芳基；R2是氢原子、较低烷基基团、较低烯烃基团或较低炔烃基团，或是具有取代基的芳基、芳基烷基或杂环芳基；R3是氢原子或较低烷基基团；R4是氢原子、卤素原子、羟基、较低烷基基团或—N(R1k)R1m基团；T和U是氮原子或亚甲基基团等。该发明的化合物具有出色的Weel激酶抑制作用，因此在药物领域中特别适用于治疗各种癌症。

  公开号：

  US20070254892A1

文献信息

• [EN] SUBSTITUTED PARA-BIPHENYLOXYMETHYL DIHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF<br/>[FR] PARA-BIPHÉNYLOXYMÉTHYL-DIHYDRO-OXAZOLOPYRIMIDINONES SUBSTITUÉES, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：SANOFI AVENTIS

  公开号：WO2011034828A1

  公开（公告）日：2011-03-24

  The present invention relates to a series of substituted para-biphenyloxymethyl dihydro oxazolopyrimidinones of formula (I) as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, cognition deficit disorders, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

  本发明涉及一系列以本文所定义的式(I)的取代对联苯氧甲基二氢噁唑吡咯嘧啶酮。本发明还涉及制备这些化合物的方法，包括新颖的中间体。本发明的化合物是代谢型谷氨酸受体（mGluR），特别是mGluR2受体的调节剂。因此，本发明的化合物在药物代理方面是有用的，特别是在治疗和/或预防各种中枢神经系统疾病（CNS），包括但不限于急性和慢性神经退行性疾病、精神病、认知缺陷症、癫痫、焦虑、抑郁、偏头痛、疼痛、睡眠障碍和呕吐等方面。
• Dihydropyrazolopyrimidinone derivatives
  申请人：Sagara Takeshi

  公开号：US20070254892A1

  公开（公告）日：2007-11-01

  The invention relates to compounds of a general formula (I): wherein Ar 1 is an optionally-substituted aryl or heteroaromatic group; R 1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 3 is a hydrogen atom or a lower alkyl group; R 4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R 1k )R 1m ; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

  该发明涉及一般式（I）的化合物，其中Ar1是可选择取代的芳基或杂环芳基；R1是可选择取代的较低烷基、较低烯烃基、较低炔烃基或环状较低烷基基团，或是具有取代基的芳基、芳基烷基或杂环芳基；R2是氢原子、较低烷基基团、较低烯烃基团或较低炔烃基团，或是具有取代基的芳基、芳基烷基或杂环芳基；R3是氢原子或较低烷基基团；R4是氢原子、卤素原子、羟基、较低烷基基团或—N(R1k)R1m基团；T和U是氮原子或亚甲基基团等。该发明的化合物具有出色的Weel激酶抑制作用，因此在药物领域中特别适用于治疗各种癌症。
• Cr³⁺-Mediated Addition of Arylzincs to Aldehydes
  作者：Yoshihiro Ogawa、Mitsuo Mori、Akihiro Saiga、Kentaro Takagi

  DOI：10.1246/cl.1996.1069

  日期：1996.12

  Addition of arylzincs to aldehydes was achieved by making use of the novel transmetallation of arylzincs into Cr3+ compounds. Various α-substituted benzyl alcohols or 3-substituted 1(3H)-isobenzofuranones, containing reactive functional groups, were synthesized in good yields. Me3SiCl exerted beneficial effects on the reaction.

  通过将芳基锌转化为 Cr3+ 化合物的新型转金属化反应，实现了芳基锌对醛的加成。采用多种包含反应性官能团的 α-取代苄醇或 3-取代 1(3H)-异苯并呋喃酮，在良好的产率下被合成。Me3SiCl 对反应产生了有益的影响。
• Iridium-catalyzed synthesis of β-methylated secondary alcohols using methanol
  作者：Ao Song、Shiyuan Liu、Mingchun Wang、Yao Lu、Rongzhou Wang、Ling-Bao Xing

  DOI：10.1016/j.jcat.2022.01.021

  日期：2022.3

  A general synthesis of β-methylated secondary alcohols via tandem α-methylation/transfer hydrogenation from non-methylated ketones with methanol by a Cp*Ir complex [Cp*Ir(2,2′-bpyO)(OH)]Na with a bipyridine-based functional ligand was reported. Remarkably, β-methylated secondary alcohols can be obtained under milder reaction conditions using methanol as the methylating agent (C1 source) by employing

  通过 Cp*Ir 配合物 [Cp*Ir(2,2'-bpyO)(OH)]Na 与联吡啶，通过非甲基化酮与甲醇的串联α -甲基化/转移氢化合成β -甲基化仲醇报道了基于 的功能性配体。值得注意的是，通过采用该催化体系，使用甲醇作为甲基化剂（C1 源），可以在较温和的反应条件下获得β-甲基化仲醇。具有不同官能团的各种结构多样的酮被甲基化和氢化，具有良好的耐受性，产率从公平到高。该方法为使用甲醇制备β-甲基化仲醇提供了一种容易获得且高效的途径。
• DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES
  申请人：Sagara Takeshi

  公开号：US20110189130A1

  公开（公告）日：2011-08-04

  The invention relates to compounds of a general formula (I): wherein Ar 1 is an optionally-substituted aryl or heteroaromatic group; R 1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 3 is a hydrogen atom or a lower alkyl group; R 4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R 1k )R 1m ; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

  本发明涉及一般式(I)的化合物：其中Ar1是可选取代的芳基或杂环芳基基团；R1是可选取代的低碳基、低烯基、低炔基或环-低碳基基团，或是带有取代基的芳基、芳基烷基或杂环芳基基团；R2是氢原子、低碳基、低烯基或低炔基，或是带有取代基的芳基、芳基烷基或杂环芳基基团；R3是氢原子或低碳基；R4是氢原子、卤素原子、羟基、低碳基或—N(R1k)R1m基团；T和U是氮原子或甲基基团等。该发明的化合物具有出色的Weel激酶抑制作用，因此在药物领域，特别是治疗各种癌症方面非常有用。